Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Northwest Biotherapeutics (NWBO) Other Non Operating Income (2016 - 2025)

Northwest Biotherapeutics' Other Non Operating Income history spans 14 years, with the latest figure at $6.2 million for Q4 2025.

  • Quarterly results put Other Non Operating Income at $6.2 million for Q4 2025, up 137.97% from a year ago — trailing twelve months through Dec 2025 was -$9.6 million (up 61.52% YoY), and the annual figure for FY2025 was $4.9 million, up 134.15%.
  • Other Non Operating Income for Q4 2025 was $6.2 million at Northwest Biotherapeutics, up from -$4.0 million in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $58.5 million in Q3 2021 to a low of -$93.7 million in Q4 2021.
  • The 5-year median for Other Non Operating Income is -$1.6 million (2023), against an average of -$4.5 million.
  • Peak annual rise in Other Non Operating Income hit 5225.0% in 2022, while the deepest fall reached 6200.74% in 2022.
  • Year by year, Other Non Operating Income stood at -$93.7 million in 2021, then surged by 97.29% to -$2.5 million in 2022, then soared by 569.43% to $11.9 million in 2023, then crashed by 238.15% to -$16.4 million in 2024, then skyrocketed by 137.97% to $6.2 million in 2025.
  • According to Business Quant data, Other Non Operating Income over the past three periods came in at $6.2 million, -$4.0 million, and -$4.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.